The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts

Steffan T. Nawrocki(University of Arizona), David J. McConkey(Johns Hopkins University), Ryan Takamori(The University of Texas MD Anderson Cancer Center), Bridget Sweeney‐Gotsch(The University of Texas MD Anderson Cancer Center)
Molecular Cancer Therapeutics
January 1, 2004
10.1158/1535-7163.59.3.1
Cited by 134

Related Papers

Comprehensive molecular characterization of urothelial bladder carcinoma
|Nature|2014|3.1k
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
|Cell|2017|2.5k
A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
|European Urology|2019|1.4k
Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
|European Urology|2017|798
Survivin: Key Regulator of Mitosis and Apoptosis and Novel Target for Cancer Therapeutics
|Clinical Cancer Research|2008|782